Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that was declared a global pandemic in March 2020 by the WHO. During the time since it emerged into a global crisis, there have been several recommendations to prevent spread of infection and to manage COVID-19 infected patients through supportive care, plasma therapy, oxygen support, and support of other affected vital organs.
Treatment options for COVID-19 are now emerging through several global clinical trials on antivirals, and the Indian Medical Association (Maharasthra) welcomes you to a live webinar to understand the use of antiviral Favipiravir in treatment of COVID-19 patients. During this webinar supported by Glenmark Pharmaceuticals, phase 3 clinical trial (CT) outcomes with Flavipiravir will be presented for the information of health care professionals.
The key points discussed during webinar will be as follows:
Antivirals in COVID-19
- Why treatment with antiviral is a key?
- Timing of antiviral treatment- Hit Early, Hit Hard
Favipiravir Snapshot
- Molecule Profile
- Current Global Status
Indian RCT – Topline Results
- Study design
- Efficacy Outcomes
- Safety Outcomes
Introduction & context Setting (5 Mins)
Dr. Sagar Panchal (M.B.B.S, M.D (Pharmacology))
Favipiravir in treatment of Covid-19 | Indian Phase 3 CT Outcomes (40 Mins)
Dr. Sagar Panchal (M.B.B.S, M.D (Pharmacology)
Panel Discussion, Q & A (40 min)
Dr. Swami Pawar (MBBS, MD Chest)
Dr. Swapnil Gautam (MBBS, MD, DNB, MNAMS, PGDMLS)
Summary & Vote of thanks (5 mins)
Dr. Sagar Panchal (M.B.B.S, M.D (Pharmacology)
Dr Avinash Bhondwe (IMA-MS President)
Dr Pankaj Bandarkar (IMA-MS Hon Secretary)
